EVLO Share Price | Evelo Biosciences, Inc. Stock Analysis & Recommendation

Q: Who are in the management team of Evelo Biosciences, Inc.?

As of March 2022, the management team of Evelo Biosciences, Inc. includes Mr. David Epstein as the Chairman of the Board and Dr. Balkrishan Gill, who serves as the President, Chief Executive Officer, Principal Financial Officer, Treasurer, and Director. Additionally, the Board of Directors features several independent directors: Mr. Juan Andres, Prof. Lord Ara Darzi, Mr. Theodose Melas-Kyriazi, Mr. David Perry, and Dr. Nancy Simonian. In summary, as of March 2022, Evelo Biosciences, Inc. is led by Mr. David Epstein and Dr. Balkrishan Gill, with a diverse Board of Directors comprising independent members.

Q: Is Evelo Biosciences, Inc. technically bullish or bearish?

As of 7 May 2025, the technical trend for Evelo Biosciences, Inc. has changed from sideways to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend and the weekly RSI showing bearish momentum. While the MACD is mildly bullish on both weekly and monthly time frames, the overall sentiment is tempered by the bearish weekly RSI. The stock has shown a significant 1-year return of 400%, outperforming the S&P 500's 17.14%, but has declined by 100% over the last 3, 5, and 10 years, contrasting sharply with the S&P 500's gains during those periods.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

140

Shareholding (Dec 2023)

FII

2.36%

Held by 26 FIIs

DII

39.77%

Held by 9 DIIs

Promoter

49.84%

How big is Evelo Biosciences, Inc.?

22-Jun-2025

As of Jun 18, Evelo Biosciences, Inc. has a market capitalization of 0.01, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -82.34 million over the last four quarters. Shareholder's funds are reported at -4.99 million, and total assets amount to 64.44 million.

View full answer

Who are in the management team of Evelo Biosciences, Inc.?

22-Jun-2025

As of March 2022, Evelo Biosciences, Inc. is led by Chairman Mr. David Epstein and CEO Dr. Balkrishan Gill, with a Board of Directors that includes independent members such as Mr. Juan Andres and Prof. Lord Ara Darzi.

View full answer

Is Evelo Biosciences, Inc. technically bullish or bearish?

20-Sep-2025

As of May 7, 2025, Evelo Biosciences, Inc. is in a mildly bearish trend despite a strong 400% one-year return, influenced by bearish daily moving averages and a bearish weekly RSI, while the stock has declined by 100% over the last 3, 5, and 10 years.

View full answer

Compare Evelo Biosciences, Inc. with Similar Stocks

Alpha Teknova, Inc.Kronos Bio, Inc.Werewolf Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.62

Return on Equity

297.83%

Price to Book

-0.00

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2023)

Net Profit:

-12 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-80.0%

6 Months

-80.0%

1 Year

-75.0%

2 Years

-99.76%

3 Years

-99.99%

4 Years

-100.0%

5 Years

-100.0%

Evelo Biosciences, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-12.00%

EBIT to Interest (avg)

-45.39

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.62

Sales to Capital Employed (avg)

Tax Ratio

1.09%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

71.92%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

-0.00

EV to EBIT

-0.23

EV to EBITDA

-0.24

EV to Capital Employed

-1.67

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bullish

Bollinger Bands

Sideways

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 18 Schemes (8.03%)

Foreign Institutions

Held by 26 Foreign Institutions (2.36%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Sep 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2023 is 59.48% vs 9.20% in Sep 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.20",
          "val2": "-27.40",
          "chgp": "62.77%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.20",
          "val2": "0.80",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.80",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-12.40",
          "val2": "-30.60",
          "chgp": "59.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 6.30% vs -30.42% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-103.50",
          "val2": "-111.30",
          "chgp": "7.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "4.70",
          "val2": "3.60",
          "chgp": "30.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.50",
          "val2": "-3.20",
          "chgp": "84.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-114.50",
          "val2": "-122.20",
          "chgp": "6.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY

Sep'23

Sep'22

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-10.20

-27.40

62.77%

Interest

1.20

0.80

50.00%

Exceptional Items

-0.80

0.00

Consolidate Net Profit

-12.40

-30.60

59.48%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2023 is 0.00% vs 0.00% in Sep 2022

Consolidated Net Profit

YoY Growth in quarter ended Sep 2023 is 59.48% vs 9.20% in Sep 2022

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'22

Dec'22

Dec'21

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-103.50

-111.30

7.01%

Interest

4.70

3.60

30.56%

Exceptional Items

-0.50

-3.20

84.38%

Consolidate Net Profit

-114.50

-122.20

6.30%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2022 is 0.00% vs 0.00% in Dec 2021

Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 6.30% vs -30.42% in Dec 2021

All Annual Results

Company CV

About Evelo Biosciences, Inc.

Evelo Biosciences, Inc.

Pharmaceuticals & Biotechnology

Evelo Biosciences, Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066, EDP1815, and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis, atopic dermatitis, rheumatoid arthritis, and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases, such as colorectal cancer, renal cell carcinoma, and melanoma among others.

Company Coordinates

Company Details

620 Memorial Dr Ste 200 , CAMBRIDGE MA : 02139-4815

Tel: 1 617 8708281

https://evelobio.com/

Registrar Details

Evelo Biosciences, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Evelo Biosciences, Inc.?

Watch in Real-Time

Who are in the management team of Evelo Biosciences, Inc.?

Is Evelo Biosciences, Inc. technically bullish or bearish?

Compare Evelo Biosciences, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'23 - YoY

Annual Results Snapshot (Consolidated) - Dec'22

About Evelo Biosciences, Inc.

Company Coordinates